US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITITM

Research Grant

Duke Scholars

Principal Investigator Andrea Sitlinger Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Innate Pharma

Start Date

September 2, 2021

End Date

February 14, 2026

Administered By

Duke Cancer Institute

Awarded By

Innate Pharma

Start Date

September 2, 2021

End Date

February 14, 2026